Eylea Race Continues To Heat Up With Formycon Unveiling Early Positive Data
Eylea Race Continues To Heat Up With Formycon Unveiling Early Positive Data
Executive Summary
Weeks after Coherus BioSciences put pen to paper on a deal to bring in Formycon’s FYB203 proposed biosimilar to Eylea (aflibercept), the candidate has shown positive efficacy and safety data, according to preliminary Phase III trial results.
You may also be interested in...
Will Biosimilar Competition And Product-Hopping Save Regeneron’s Eylea Or Cancel Each Other Out?
Biosimilar entrants look to help protect Regeneron’s currently marketed form of Eylea from the US’s new price negotiation law. But it likely hinges on how CMS views the company’s product-hopping plan.
Unpicking The CMS Guide On Price Negotiation: A Dive Into The US Eylea Biosimilar Landscape
Generics Bulletin looks at the implications and takeaways for biosimilar sponsors following the recent publication of long-awaited CMS guidance on price negotiation under the Inflation Reduction Act.
Biocon Biologics CEO On Interchangeability Dynamics For Humira Biosimilar
Biocon Biologics’ CEO indicates that interchangeability may not be pivotal to commercial success in the US for biosimilar adalimumab and that the firm’s Humira rival “checks the key boxes.”